Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Escudos moleculares para aumentar la biodisponibilidad de productos biofarmacéuticos en la circulación

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOIE20161004001
Publicado:
20/10/2016
Caducidad:
20/10/2017
Resumen:
Una pyme irlandesa del sector biofarmacéutico está desarrollando una tecnología de escudos moleculares capaz de aumentar la biodisponibilidad de productos biológicos, fragmentos de anticuerpos, anticuerpos de dominio, vacunas de subunidades y vacunas de péptidos en la circulación. La tecnología se traduce en una reducción de la frecuencia de dosificación, efectos secundarios y costes. El objetivo general es aumentar la eficacia y reducir los riesgos relacionados con la gestión de enfermedades. La empresa busca socios potenciales con el fin de establecer acuerdos de financiación, joint venture, licencia o investigación.

Details

Tittle:
Molecular shields for increasing the bioavailability of bio-pharmaceuticals in the circulation.
Summary:
An Irish SME in the biopharmaceutical field is developing molecular shields technology which is capable of increasing the bioavailability of biologics, antibodies fragments, domain antibodies, subunit vaccines -Y- peptide vaccines in the circulation. The technology translates into reduced dosing frequency, decreased side effects -Y- cost savings.

They seek to engage with potential partners in opportunities focusing on financial, joint venture, license -Y-/or research co-operation agreements.
Description:
This technology comprises molecular shields. The shield can be attached and or conjugated to a biologics of interest. The shield increases biologics bioavailability and thus its efficacy in the circulation. The technology offers better patient compliance. The overall purpose is to increase efficacy and reduce risks associated with disease management. The technology is applicable to biologics that include therapeutic recombinant proteins, peptides, subunit and peptide vaccines and antibody fragments and domain antibodies. The applications cover the areas of human health, animal health, cosmetics and skincare.

The Irish biopharmaceutical company is looking to engage with potential partners in opportunities focusing on financial, joint venture, license -Y-/or research co-operation agreements. These can be in a single agreement format or mixed depending on the discussions derived from expressions of interest.
Advantages and Innovations:
Compared to prevailing technologies;

The technology is simpler, cost effective and practical on an industrial scale.

The molecular shields can be used genetically or by conjugation means.
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Patent applications to be filed.

Partner sought

Type and Role of Partner Sought:
The company are seeking partners for financial, joint venture, license -Y-/or research co-operation agreements. Prospective partners would be pharmaceutical and biotechnology companies as co-developers and strategic partners for joint development of bio-pharmaceuticals.

Client

Type and Size of Client:
Industry SME <= 10
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English

Keywords

Technology Keywords:
06002002 Biología celular y molecular
06002001 Bioquímica / biofísica